Research

Application of a population-based severity scoring system to individual patients results in frequent misclassification

Frank V Booth1, Mary Short2, Andrew F Shorr3, Nancy Arkins4, Becky Bates5, Rebecca L Qualy6 and Howard Levy7

1Medical Fellow, Eli Lilly and Company, Indianapolis, IN, USA
2Associate Clinical Research Scientist, Eli Lilly and Company, Indianapolis, IN, USA
3Associate Director of Pulmonary Critical Care Medicine, Pulmonary and Critical Care Medicine, Washington Hospital Center, Washington, DC, USA and Associate Professor of Medicine, Georgetown University, Washington, DC, USA
4Senior Clinical Development Associate, Eli Lilly and Company, Indianapolis, IN, USA
5Associate Senior Statistician, Eli Lilly and Company, Indianapolis, IN, USA
6Senior Scientific Communication Associate, Eli Lilly and Company, Indianapolis, IN, USA
7Medical Director, Eli Lilly and Company, Indianapolis, IN, USA

Corresponding author: Frank V Booth, boothfv@lilly.com

Received: 6 May 2005 Revisions requested: 15 Jun 2005 Revisions received: 1 Jul 2005 Accepted: 12 Jul 2005 Published: 9 Aug 2005

Critical Care 2005, 9:R522-R529 (DOI 10.1186/cc3790)
This article is online at: http://ccforum.com/content/9/5/R522
© 2005 Booth et al.; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Introduction APACHE II (AP2) was developed to allow a systematic examination of intensive care unit outcomes in a risk adjusted manner. AP2 has been widely adopted in clinical trials to assure broad consistency amongst different groups. Although errors in calculating the true AP2 score may not be reducible below 15%, the self-canceling effect of random errors reduces the importance of such errors when applied to large populations. It has been suggested that a threshold AP2 score be used in clinical decision making for individual patients. This study reports the AP2 scoring errors of researchers involved in a large sepsis trial and models the consequences of such an error rate for individual severe sepsis patients.

Methods Fifty-six researchers with explicit training in data abstraction and completion of the AP2 score received scenarios consisting of composites of real patient histories. Descriptive statistics were calculated for each scenario. The standard deviations were calculated compared with an adjudicated score. Intraclass correlations for inter-observer reliability were performed using Shrout-Fleiss methodology. Theoretical distribution curves were calculated for a broad range of AP2 scores using standard deviations of 6, 9 and 12. For each curve, the misclassification rate was determined using an AP2 score cut-off of ≥25. The percentage of misclassifications for each true AP2 score was then applied to the corresponding AP2 score obtained from the PROGRESS severe sepsis registry.

Results The error rate for the total AP2 score was 86% (individual variables were in the range 10% to 87%). Intraclass correlation for the inter-observer reliability was 0.51. Of the patients from the PROGRESS registry, 50% had AP2 scores in the range 17 to 28. Within this interquartile range, 70% to 85% of all misclassified patients would reside.

Conclusion It is more likely that an individual patient will be scored incorrectly than correctly. The data obtained from the scenarios indicated that as the true AP2 score approached an arbitrary cut-off point of 25, the observed misclassification rate increased. Integrating our study of AP2 score errors with the published literature leads us to conclude that the AP2 is an inappropriate sole tool for resource allocation decisions for individual patients.

Introduction

The Acute Physiology and Chronic Health Evaluation II (APACHE II) scoring system was originally developed as a tool for comparing the outcomes of acute disease in critically ill patients across multiple intensive care units in a therapy-independent fashion [1]. Although relatively few critical care units have adopted this system or its successor, APACHE III, for this purpose, APACHE II has found widespread application in clinical trials as a tool both for stratification of patient populations and as a means of demonstrating acceptable baseline
balance amongst subgroups within a given trial. In large
groups of patients, it has repeatedly been demonstrated that
there is excellent correlation between APACHE II score and
risk of death. The actual mortality risk predicted by this scoring
system varies considerably with the underlying diagnosis and
from country to country. The developers of APACHE II have
emphasized that an accurate classification of the underlying
disease state is essential for the accuracy of the predictive
model [1].

The total APACHE II score is derived by summing points from
three distinct categories: acute physiologic derangements (12
individual elements); age points; and points for the presence
of certain specific chronic health conditions or medical situa-
tions. Within the acute physiologic score, three elements
require additional decisions or preparatory calculation: the
Glasgow coma score; an assessment of pulmonary function;
and a decision if an abnormal value of creatinine represents
acute or chronic renal failure. The difficulties of reliably deter-
mining Glasgow Coma Score have been well documented. In
assessing pulmonary function, depending on the fraction of
inspired oxygen (FIO₂), either the arterial partial oxygen pres-
sure (pO₂) or the alveolar-arterial oxygen gradient (A-a DO₂)
must be used. The calculation of the latter requires the suc-
sessful application of the alveolar gas equation, which in turn
requires knowledge of average local atmospheric pressure.
These numerous and complex data manipulations required to
calculate the APACHE II score introduce many opportuni-
ties for error in the determination of an individual patient’s points
total. The combination of many elements into a composite
score means that there are literally thousands of data permu-
tations, which may be recorded to produce an identical
APACHE II score.

This retrospective study reports the APACHE II scoring error
rates for three case scenarios calculated by Clinical Research
Associates and Research Coordinators involved in a large ran-
donized placebo-controlled critical care clinical trial. We
examined the effects of these scoring error rates on the ability
to correctly classify an individual into either having an
APACHE II score above or below a cut-off score of 25. In addition,
we used a large database of patients with severe sepsis
to estimate the distribution of reported APACHE II scores.
Combining this known distribution of APACHE II scores and
our estimated misclassification rates, we estimated the overall
frequency of misclassification of individual severe sepsis
patients into categories of having an APACHE II score above
or below 25.

Methods

Study participants

Fifty-six individuals (clinical research associates (n = 17) and
study coordinators (n = 39), associated with the ADDRESS
clinical trial) returned completed case scenarios used in this
study. Demographic data on these individuals were not
obtained. All received explicit training in data abstraction and
recording for the ADDRESS trial, a multi-institutional investiga-
tion of drotrecogin alfa (activated) in severe sepsis. Study pro-
cedures for this trial required that APACHE II score be
obtained at baseline, either from the medical record if this cal-
culation was part of the clinical routine at the specific institu-
tion or as a study-specific determination. The study coordinators
came from individual participant sites in the
ADDRESS trial and were either employees or associates of
the principal investigators at those sites. The clinical research
associates were either employees of Eli Lilly and Company or
of a contract research organization engaged by Lilly to assist
in the conduct of the ADDRESS trial. The case scenarios,
instructions and scoring sheets for APACHE II were distrib-
uted to the participants at the beginning of a two-day study ini-
tiation meeting and were returned at its conclusion.
Participants completed these forms individually. No con-
straints were applied on the time allowed for completion. Par-
ticipants were given the option of returning the score sheets
anonymously or with their names included (for the purpose of
receiving feedback). Almost without exception, score sheets
were returned bearing the participant’s name, but were subse-
quently obliterated and replaced with an anonymous identifier
for the purposes of data analysis for this study.

Case scenarios

Three individual case scenarios were developed using com-
posites of real patient histories and laboratory values. Each
scenario consisted of several elements but all contained at a
minimum: a multi-page critical-care vital signs flow sheet (with
multiple and frequent observations of pulse rate, blood pres-
sure, respiratory rate, components of the Glasgow coma
score, etc.); and a laboratory values report in the form of a
spreadsheet, typically covering a 48 h period and including
18 routine chemistries, cardiac enzymes, arterial and venous
blood gas values as well as routine hematology results. The
third element of the scenario was a narrative summary of the
patient’s clinical course. In many cases this summary con-
tained items of relevance to the calculation of an APACHE II
score, such as times of landmark events, and physiologic val-
ues observed in the pre-hospital or emergency room environ-
ment. The participants were given a standardized APACHE II
scoring sheet and instruction set.

Adjudicated APACHE II score

Two of the authors (MS and FVMcLB) independently scored
each clinical scenario on two separate occasions approxi-
ately two weeks apart. A consensus-forming session was
then held at which every individual contributing element of the
APACHE II score was reviewed, agreed upon and an adju-
dicated point value determined. For one of the scenarios
(APACHE II score = 22) the agreed aggregate point value was
identical to the value calculated by the two observers inde-
pendently. For the other two, an adjustment of a single point
Figure 1

Results of the scoring exercise. The results of the scoring exercise completed by researchers involved in a large randomized placebo-controlled critical care trial illustrating individual scores, standard deviations and inter-quartile ranges of case scenarios with adjudicated total APACHE II scores of 44, 22 and 19. 1Correct classification is determined by the adjudicated score being either APACHE II ≥25 or APACHE II <25. 2Standard deviation is calculated using the adjudicated APACHE II score in place of the mean APACHE II score.
was agreed upon. These consensus values were then used as the adjudicated values against which the scores of the study participants were measured.

**Statistical methodology**

Descriptive statistics (mean, median, inter-quartile range) were calculated for each scenario. The standard deviations were calculated using the adjudicated APACHE II value in place of the mean reported APACHE II score.

Intraclass correlations for inter-observer reliability were performed using Shrout-Fleiss methodology [2]. The intraclass correlation used in this study assumed the same observers scored the three scenarios, although each scenario was a random subset of all possible observers. In the second phase of this study, it was assumed that for any given population of patients with an identical true APACHE II score, the distribution of possible APACHE II scores would be approximately normal. Theoretical distribution curves were calculated for each true APACHE II score using standard deviations of 6, 9 and 12. For each distribution curve, the misclassification rate was determined in the following manner. If the true score was <25, misclassification was represented by the area of the distribution curve above or equal to 25. If the true score was ≥25, misclassification was represented by the area of the distribution curve below 25.

A large sample of APACHE II scores (n = 5,253) was obtained from the PROGRESS registry, a collaborative web-based registry of severe sepsis patients admitted to over sixty intensive care units worldwide [3]. The percentage of misclassifications for each true APACHE II score estimated in the second phase of this study was applied to the corresponding scores in this large sample of APACHE II scores. An overall misclassification rate was estimated by summing the misclassifications for each APACHE II score from this sample.

**Results**

Not every participant completed every case scenario; the completion rate was 159/168 (94.6%). Fifteen participants returned composite scores only. The three different scenarios had widely differing adjudicated APACHE II scores. The scenario with an adjudicated score of 44 was most frequently scored incorrectly (52/56, 92.9% incorrect). The accuracy of scoring was better for the other two scenarios whose adjudicated scores were markedly lower (score = 22: 45/52, 86.5% incorrect; score = 19: 41/43, 77.4% incorrect). In only two of the numerically correct total scores did the participant arrive at their answers by a balanced combination of errors.

In contrast to the scenario with a score of 44 in which all but one of the erroneous scores underestimated the true APACHE II score, the distribution of the erroneous scores assumed a more normal random distribution for scenarios with scores of 19 and 22. The intraclass correlation for the inter-

---

**Table 1**

| Error rates of combined case study data for each component of the APACHE II score | Error rates |
|-----------------------------------|-------------|
| Acute physiologic score (A)       |             |
| Temperature (rectal/core)         | 48%         |
| Mean arterial pressure            | 59%         |
| Heart rate (ventricular response) | 46%         |
| Respiratory rate (non-ventilated or ventilated) | 45% |
| Oxygenation                       | 52%         |
| Arterial pH                       | 38%         |
| Serum sodium                      | 29%         |
| Serum potassium                   | 26%         |
| Serum creatinine                  | 43%         |
| Hematocrit                        | 33%         |
| White blood count                 | 49%         |
| Glasgow Coma Scale                | 69%         |
| Total acute physiology score (A)  | 87%         |
| Age points (B)                    | 10%         |
| Chronic health points (C)         | 34%         |
| Total APACHE II score (A+B+C)     | 86%         |

Observer reliability was 0.51, 95% CI (0.22–0.98). The results of the scoring exercise, individual scores, standard deviations and interquartile ranges are shown in Fig. 1.

Table 1 lists the error rate for each component of the APACHE II score. Fig. 2 shows the theoretical distribution curves of five true values of APACHE II scores. The areas shaded show the proportion of scores that would result in a misclassification using an APACHE II score cut-off of 25 or greater. The value of 25 was chosen because it has been suggested that this value may be used to identify a patient at high risk of death from severe sepsis. The effect of varying the assumed standard deviation is also shown. The proportion of misclassification increases as the true score approaches the cut-off score of 25. The highest rate of misclassification occurs when the true score equals the cut-off score.

Fig. 3 shows the relative frequency of APACHE II scores observed in a population of severe sepsis patients (PROGRESS Registry). The lightly shaded areas in Fig. 3 show the estimated distribution of misclassification rates of individuals with severe sepsis into groups of scores <28 and ≥25 based on the estimated misclassification rates from the theoretical distribution curves. Using this distribution of APACHE II scores from the PROGRESS registry, 50% of severe sepsis patients have APACHE II scores ranging from...
17 to 28. Within this interquartile range will reside 70% to 85% of all misclassified patients (depending on the underlying standard deviation of the APACHE II scores).

**Discussion**

Our observations concerning the accuracy and inter-observer variability of deriving APACHE II scores in a simulated clinical setting are concordant with those of Polderman et al. [4] and Chen et al. [5], although the absolute magnitude of the errors we report is larger. Fig. 1 shows the differing distributions of erroneously calculated scores. The scenario with a score of 44 has a mean and median that substantially underestimate the adjudicated APACHE II score, whereas the distribution of errors in the other two scenarios resulted in a mean and median within three APACHE II points of the adjudicated score. This would be considered statistically indistinguishable from the adjudicated value and acceptable from a scientific sampling point of view when comparing population intensive care unit outcomes, or the success of randomizing patients into subgroups with comparable severity.

Furthermore, it should be noted that in our study, Glasgow coma scores as recorded in the flow sheets were assumed to be accurate. In nursing practice, errors in reporting of Glasgow coma scores, especially for the intubated patient, are well documented [6]. APACHE II methodology requires that scores for creatinine intervals be doubled for acute renal failure. Overall, creatinine points were assessed incorrectly 43% of the time. In one of the scenarios, however, all the creatinine values were within normal limits. Thus, on the score sheets where the creatinine score should have been doubled, this step was omitted on 64 of a possible 72 (89%) occasions, making omission of this step in practice the most frequent error seen.

In this simulation the practitioners were provided with a summary clinical abstract, which was assumed to contain all the relevant clinical and time-line information. In the clinical environment such information is frequently intimately interwoven with extraneous confusing and irrelevant matter within a complex clinical chart. This likely increases the possibility that an important point of information may be overlooked. Table 1 demonstrates that even invariable information such as age was incorrectly abstracted or assigned to the incorrect interval that determines the score for that parameter, and that for many parameters an incorrect value was more likely to be assigned than a correct value. In selecting the range of standard deviation used for the illustrative theoretical curves (Fig. 2), we
relied on values observed in the case scenarios (standard deviations of 6 and 12), and arbitrarily included a standard deviation of 9.

In reviewing the technical literature of APACHE II, two distinct approaches are seen: the overall performance of the score as an outcome predictor for groups of patients; and the performance of small groups of individuals in achieving accuracy and reproducibility of the actual APACHE II score. With regard to the much more frequent reporting of overall performance of the score as an outcome predictor for groups of patients, all of these types of studies have the underlying assumption that there is a sufficiently large patient sample size to ensure that any effect of individual error in determining the APACHE II score is trivial in comparison to the underlying trend of the group as a whole. In this guise the tool has been used to predict the outcome of classes of patients as varied as those with acute pancreatitis to patients with acute community acquired pneumonia. The original authors of the APACHE II system emphasized that although the APACHE II score was highly correlated with risk of death, an individual score could not be translated into a specific risk of death without taking into account the underlying diagnosis [1]. Thus in a large group of patients, all with an APACHE II score of 22 and the same clinical diagnosis, for example pneumonia, the risk of death would be very similar. However, the risk of death would not necessarily be the same as another group of patients also with an APACHE II score of 22 who had a different underlying diagnosis, for example, ascending cholangitis. A specific example of this was cited in the original paper [1]. Despite the different weighting given to the presence of chronic health conditions in the emergency surgical patient, there was still a substantial difference in observed mortality between medical and surgical patients. APACHE II seems to perform less well in surgical patients [7]. These cited limitations clearly show that applying a single APACHE II score cut-off to determine high risk of death to all classes of patients is less than optimal.

The second type of review has focused on the performance of small groups of individuals in achieving accuracy and reproducibility of the actual APACHE II. As Rowley and Fielding [6] have shown, inter-rater reliability alone is insufficient grounds for confidence in the accuracy of real-world APACHE II scores. In studies where the accuracy of an individual APACHE II determination is the main focus of attention, the number of cases that can be studied is necessarily limited given the intensive effort required to determine what the 'gold standard' value really is. We are not aware of any studies that attempt to examine the consequences of random or systematic errors on the performances of the APACHE II predictive model.

Although the absolute rate of erroneous APACHE II score determination that we have reported appears to be higher than that reported either by Polderman et al. [4] or Chen et al. [5],
this may be largely attributable to the greater severity of physiologic derangements used in our simulations. Thus, the mean and median APACHE II score in Polderman’s repeat scoring exercise was 14.3 (± 4.4) and 13.9 before rigorous training and 18.9 (± 2.4) and 16.2 after training. They do not provide adjudicated or ‘gold standard’ values for the individual patients they studied, so that strict comparisons of accuracy as opposed to inter-rater agreement cannot be made. The simulations used had APACHE II scores of 19, 22 and 44. The opportunity for error rises almost geometrically with the number of deranged physiologic variables, which likely explains the higher standard deviation we observed in the simulations with the higher APACHE II scores. The overall inter-class correlation which we report (0.51) lies between the simulations with the higher APACHE II scores. The overall intra-class correlation which we report (0.51) lies between the worst individual component value reported by Chen et al. [5] (for Glasgow Coma Score at 0.315) and the best (for age at 0.976). We did not perform intra-class correlations for individual elements of the APACHE II score. Despite the intrinsic variability noted by Chen et al. [5], when groups of patients were compared (as was intended by the designers of the original tool) the correlation was excellent.

The inter-rater reliability noted in this investigation (0.51) can, at best, be described as only fair. From a research perspective this underscores the potential bias in any critical care study relying on the APACHE II score either for entry into a trial or for analysis of baseline severity of illness. Moreover, if in the future novel therapies are to be targeted based on such a criterion, many patients eligible for a therapy may be excluded whereas others may be treated inappropriately. That we studied only trained researchers reinforces this point, as it seems reasonable to conclude that less specifically trained personnel or clinicians will likely make more errors in the computation of the APACHE II score. Future research in critical care might include multiple measures of severity of illness to address this limitation.

Recently, it has been suggested that the APACHE II score may be a useful tool to determine if a patient has a sufficient risk of death to warrant treatment with drotrecogin alfa (activated). For a population of severe sepsis patients enrolled in the PROWESS trial [8], the APACHE II score was the strongest indicator for distinguishing patients with a response to the drug from the group that did not show a positive response [8]. Explicitly, the current US package insert for drotrecogin alfa (activated) proposes an APACHE II score of 25 or greater as a way to determine if a patient is at high risk of death [9]. Even if it is assumed that APACHE II methodology is perfect for resolving the arbitrary distinction between high risk of death and not at high risk of death, the error rate in determining the APACHE II score, which others have reported and which we have confirmed, will ensure that significant numbers of patients will be misclassified (i.e. they will be assigned to one side of a 25 point threshold when their true score lies on the other). There is a fundamental practical difference between using a scoring system such as APACHE II for examining likelihood of death, and using it to determine if a severe sepsis patient lies above or below an arbitrary threshold. In any given intensive care unit population; the majority of survivors are clustered at the low end of the APACHE II score range. Deaths are concentrated at the high end. If, in a population of patients, the observed mortality is plotted against APACHE II score, at the low end of the range the curve is quite flat. A change of score from 4 to 8 makes little difference to mortality; the vast majority still survive. Likewise, at the upper end of the range, above a score of about 40, most patients die, and increasing the score by two or three points changes the mortality little. In the mid-range of the curve, however, the mortality versus APACHE II score is very steep. A change of one or two points makes a large difference in the observed change in mortality. Thus, when using a cut-off point that happens to lie in the steepest region of the curve, the significance of scoring errors is maximized. The closer a patient’s true APACHE II score approaches the cut-off point of 25, the higher the misclassification rate (this trend is illustrated in Fig. 2). Unfortunately, a cut-off value of 25 sits uncomfortably close to the median APACHE II score of 22, seen in severe sepsis patients admitted to intensive care units included in the PROGRESS registry (Fig. 3). The chance of misclassification for a patient lying within the inter-quartile range (17 to 28) is estimated to be as high as 38%. This set of patients represents the population of severe sepsis patients admitted to the intensive care unit for whom the outcome is most in doubt. Because the APACHE II scoring error rate estimates are based on a normal distribution around the true APACHE II score, these misclassification rates are conservative in nature, as the maximum misclassification rate can only be 50%. The real world distributions of scoring errors, such as seen in the scenario with APACHE II score of 22, suggest that occasionally the misclassification rate can exceed 50%. If such a score is to be used in a medical decision making process, the likely error rate should be clearly understood, and serious attention should be paid to maximizing the expertise and accuracy of those responsible for the scoring process.

**Conclusion**

It is far more likely that an individual patient will be scored incorrectly than correctly, even by a group of individuals trained in scoring and chart abstraction. Even the scenario with an adjudicated APACHE II score that placed it many points distant from an arbitrary cut-off point of 25 was misclassified at an unacceptably high rate. Observed misclassification rate for the scenario with an adjudicated score within 3 points of the cut-off was over 50%. Integrating our study of APACHE II score errors with the published literature leads us to conclude that the APACHE II is an inappropriate sole tool for resource allocation decisions for individual patients.
**Key messages**

- There are typically errors in execution of a complex scoring scheme such as APACHE II.
- These errors do not have a significant effect when applied to patient populations of a sufficient size.
- If a cut-off APACHE II score in the middle range of critically ill patients is used for making decisions about individual patients, an error rate that may be considered acceptable for use with sufficiently large patient populations will produce a very high rate of misclassification in those individuals so classified.

**Competing interests**

FVMcLB, MS, NA, BB, RLQ and HL are full-time employees and shareholders of Eli Lilly and Company. AFS has been a paid consultant and speaker for Eli Lilly and Company.

**Authors’ contributions**

All the authors have contributed to the composition, revision and review of the manuscript and have read and approved the final version. In addition, FVMcLB and MS conceived of the idea for this manuscript, BB performed the statistical analysis, RLQ edited the document and BB participated in obtaining the original PROWESS data.

**References**

1. Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829.
2. Shrout PE, Fleiss JL: Intraclass correlations: uses in assessing rater reliability. Psychological Bulletin 1979, 86:420-429.
3. Beale R, Reinhart K, Silva E, Dobb G, Sarwat S, Garg R, Vincent JL: Comparison of PROGRESS Severe Sepsis Registry patients to INDEPTH Integrated Severe Sepsis Clinical Trial Database placebo patients. Chest Meeting Abstracts; Chest 2004, 126:864S. Abstract #496
4. Polderman KH, Thijs LG, Girbes AR: Interobserver variability in the use of APACHE II scores. Lancet 1999, 353:380.
5. Chen LM, Martin CM, Morrison TL, Sibbald WJ: Interobserver variability in data collection of the APACHE II score in teaching and community hospitals. Crit Care Med 1999, 27:1999-2004.
6. Rowley G, Fielding K: Reliability and accuracy of the Glasgow Coma Scale with experienced and inexperienced users. Lancet 1991, 337:535-538.
7. Cerra FB, Negro F, Abrams J: APACHE II score does not predict multiple organ failure or mortality in postoperative surgical patients. Arch Surg 1990, 125:519-522.
8. Bernard GR, Vincent J-L, Laterre PF, LaRosa SP, Dhainaut J-F, Lopez-Rodriguez A, Steingrub JS, Garber GE, Heterbrand JD, Ely EW, et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709.
9. Drotrecogin Alfa (activated) Product Label [http://pi.lilly.com/us/xigris.pdf]